- Home
- SELF vs IRD Comparison
SELF vs IRD Comparison
Compare SELF & IRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SELF
- IRD
- Stock Information
- Founded
- SELF 1983
- IRD 2018
- Country
- SELF United States
- IRD United States
- Employees
- SELF N/A
- IRD N/A
- Industry
- SELF Real Estate Investment Trusts
- IRD
- Sector
- SELF Real Estate
- IRD
- Exchange
- SELF Nasdaq
- IRD NYSE
- Market Cap
- SELF 56.9M
- IRD 62.0M
- IPO Year
- SELF N/A
- IRD N/A
- Fundamental
- Price
- SELF $5.39
- IRD $1.02
- Analyst Decision
- SELF
- IRD Strong Buy
- Analyst Count
- SELF 0
- IRD 3
- Target Price
- SELF N/A
- IRD $6.33
- AVG Volume (30 Days)
- SELF 28.1K
- IRD 803.8K
- Earning Date
- SELF 08-08-2025
- IRD 08-15-2025
- Dividend Yield
- SELF 5.38%
- IRD N/A
- EPS Growth
- SELF 15.74
- IRD N/A
- EPS
- SELF 0.22
- IRD N/A
- Revenue
- SELF $12,622,544.00
- IRD $13,651,000.00
- Revenue This Year
- SELF N/A
- IRD $51.41
- Revenue Next Year
- SELF N/A
- IRD $68.84
- P/E Ratio
- SELF $24.51
- IRD N/A
- Revenue Growth
- SELF 3.58
- IRD N/A
- 52 Week Low
- SELF $4.70
- IRD $0.65
- 52 Week High
- SELF $5.89
- IRD $2.18
- Technical
- Relative Strength Index (RSI)
- SELF 45.98
- IRD N/A
- Support Level
- SELF $5.26
- IRD N/A
- Resistance Level
- SELF $5.49
- IRD N/A
- Average True Range (ATR)
- SELF 0.15
- IRD 0.00
- MACD
- SELF -0.03
- IRD 0.00
- Stochastic Oscillator
- SELF 42.11
- IRD 0.00
About SELF Global Self Storage Inc.
Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to 13 self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
About IRD OPUS GENETICS INC
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.